英夫利西单抗和来氟米特联用治疗早期严重类风湿性关节炎

目的了解英夫利西单抗及来氟米特联合应用对早期严重类风湿性关节炎的临床疗效。方法 87例早期严重类风湿性关节炎患者随机分为英夫利西单抗组、英夫利西单抗联合来氟米特组及来氟米特组,治疗前作相应的临床、实验室检查后,英夫利西单抗以每次剂量3mg/kg静滴,0,2,6周以后每隔8周用药1次;来氟米特20mg/d,治疗后对患者临床观察指标进行比较,并进行疗效评价。结果英夫利西单抗联合来氟米特组治疗24周后,关节炎症状明显得以控制,达到美国风湿学会症状体征20%改善(ACR20)、美国风湿学会症状体征50%改善(ACR50)、美国风湿学会症状体征70%改善(ACR70)的分别为90%、66%及34%,与另外二组比较差异有统计学意义(P<0.01)。结论英夫利西单抗与来氟米特联合应用对早期严重类风湿性关节炎有显著疗效。

CLINICAL THERAPEUTIC EFFECT OF COMBINATION WITH INFLIXIMAB AND LEFLUNOMIDE(LEF) ON SERIOUS EARLY RHEUMATOID ARTHRITIS

Objective To observe the clinical therapeutic effect of combination with infliximab and LEF for rheumatoid arthritis(RA).Methods 87 cases were randomly divided into 3 groups:the first group were treated with the combination with infliximab and LEF,another infliximab only,the last one LEF only.All the cases were administrated corresponding clinical and laboratory examination.The American College of Rheumatology(ACR) core set was used for assessment of efficacy.Results After treated for 24 weeks the inflammation of arthritis of the groups treated with the combination with infliximab and LEF were controlled obviously,the clinical effect was more obvious than other groups(P<0.01).On the basis of ACR standard,the rate of 20% improvement,50% improvement and 70% improvement were observed in 90%(26/29),66%(19/29) and 34%(10/29)of subjects respectively.Conclusion The combination of infliximab and LEF has obvious effect on serious rheumatoid arthritis in earlier period.